14-3-3 η ETA protein as a potential marker of joint damage in gout.

Autor: Doğan İ; Ankara Yıldırım Beyazıt University Medical Faculty, Rhuematology Department, Ankara, TÜRKİYE. Electronic address: dridogan@hotmail.com., Kor A; Ankara Yıldırım Beyazıt University Medical Faculty, Rhuematology Department, Ankara, TÜRKİYE. Electronic address: ahmetkor_kor@hotmail.com., Güven SC; Ankara City Hospital, Rheumatology Department, Ankara, TÜRKİYE. Electronic address: drserdarguven@gmail.com., Fırat Oğuz E; Ankara City Hospital, Biochemistry Department, Ankara, TÜRKİYE. Electronic address: dr_esrafirat@hotmail.com., Başer S; Ankara Yıldırım Beyazıt University Medical Faculty, Internal Medicine Department, Ankara, TÜRKİYE. Electronic address: sbaser@ybu.edu.tr., Atalar E; Ankara City Hospital, Rheumatology Department, Ankara, TÜRKİYE. Electronic address: atalarebrudr@yahoo.com., Maraş Y; Ankara City Hospital, Rheumatology Department, Ankara, TÜRKİYE. Electronic address: ymaras@hotmail.com., Erel Ö; Ankara Yıldırım Beyazıt University Medical Faculty, Biochemistry Department, Ankara, TÜRKİYE. Electronic address: oerel@ybu.edu.tr., Erten Ş; Ankara Yıldırım Beyazıt University Medical Faculty, Rhuematology Department, Ankara, TÜRKİYE. Electronic address: sukranerten@yahoo.com.
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2023 Aug; Vol. 118, pp. 110611. Date of Electronic Publication: 2023 Jul 08.
DOI: 10.1016/j.clinbiochem.2023.110611
Abstrakt: Introduction: The aim of the study is to investigate serum levels of 14-3-3 η (ETA) protein in patients with gout and possible relations with joint damage.
Method: This cross-sectional study included 43 gout patients and 30 control patients.
Results: Serum 14-3-3 η protein levels were significantly higher in gout patients (median [IQR], 3.1 [2.0] vs 2.2 [1.0], p = 0.007). In subgroup analyses of gout patients, serum 14-3-3 η protein levels did not differ between patients with and without a flare, tophaceous disease, elevated CRP and serum uric acid levels and a history of chronic kidney disease; however, were significantly higher in the patients with erosions (Median [IQR], 4.1 [2.7] vs 2.7 [1.5], p = 0.002). According to ROC curve, serum 14-3-3 η protein had 86.0% sensitivity and 30% specifity at a cut-off point of 1.7 ng/mL and had 74.7% sensitivity and 43.3% specifity at a cut-off point of 2.0 ng/mL.
Conclusion: Our results demonstrated elevated levels of 14-3-3 η protein in gout patients which is more prominent in patients with erosive changes, implying role of 14-3-3 η protein in inflammatory and structural damage related pathways and suggesting a potential as a marker for disease severity.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: